Last reviewed · How we verify
Exenatide IV
Exenatide IV, marketed by the Carl T. Hayden VA Medical Center, is an intravenous formulation of exenatide with a key composition patent expiring in 2028. The drug's primary strength lies in its established market presence and unique delivery method. The primary risk is the potential for increased competition post-patent expiry in 2028.
At a glance
| Generic name | Exenatide IV |
|---|---|
| Also known as | exendin-4, Byetta |
| Sponsor | Carl T. Hayden VA Medical Center |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Comparative Effectiveness and Safety of Four Second Line Pharmacological Strategies in Type 2 Diabetes Study
- Pharmacogenomics of GLP1 Receptor Agonists (PHASE1)
- Islet Transplantation in Type 1 Diabetic Patients Using the University of Illinois at Chicago (UIC) Protocol (PHASE3)
- Pathophysiological Study of the Increase in Pancreatic Volume in Type 2 Diabetes Treatments. (NA)
- Intravenous Exenatide (Byetta) During Surgery (PHASE1, PHASE2)
- Islet Transplantation in Type 1 Diabetic Patients Using the Edmonton Protocol of Steroid Free Immunosuppression (PHASE1, PHASE2)
- A 12/24-weeks, Open, Multi-centre, Phase IV Study on Safety and Efficacy of 2mg Exenatide Once Weekly (Bydureon) in T2DM Patients. (PHASE4)
- Intravenous Exenatide in Patients With Acute Brain Injury (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Exenatide IV CI brief — competitive landscape report
- Exenatide IV updates RSS · CI watch RSS
- Carl T. Hayden VA Medical Center portfolio CI